What’s on the Horizon for Radiation Oncology in 2026?

The year 2026 is primed to be a big one for the radiation oncology space. CancerNetwork^® and the journal ONCOLOGY^® will be at the forefront of the latest and greatest happenings in the field.

With the help of editor-at-large Brandon Mancini, MD, MBA, FACRO, radiation oncology will be the centerpiece of new original research, in-depth discussions, and other exclusive coverage exploring the modality from all possible angles. Mancini, the director at BAMF Health and a clinical associate professor in the Department of Radiology at Michigan State University College of Human Medicine, will oversee The RadOnc Review, a brand-new supplement of ONCOLOGY. Attempting to bridge a gap in the field, this quarterly, peer-reviewed supplement will be a resource for radiation oncologists to share their work and learn about investigations in the field. This supplement will be PubMed-indexed under ONCOLOGY and is currently accepting all major manuscript types.

For those who enjoy listening in on the newest events, data, and technologies that are propelling radiation oncology forward, our new podcast RadOnc on the Run will serve as another valuable platform for keeping up to date. In this special podcast series, Mancini will guide listeners on critical findings from the latest oncology conferences and studies while sharing considerations for strengthening the use of radiotherapy as part of a multidisciplinary care plan. From evergreen talks on billing and policy to thorough breakdowns of star presentations at meetings like the American Society for Radiation Oncology Annual Meeting (ASTRO), Mancini and colleagues will discuss the many vital roles radiation oncology can play in cancer care.

Through unique written publications and timely podcast chats, CancerNetwork and ONCOLOGY will offer a variety of ways to learn about the ever-evolving radiation oncology field in 2026.

“[We have] lots of additional resources within the radiation oncology space to ensure that radiation oncologists continue to have a voice, continue to have a focused resource that they can rely on to advance the field, and continue to have traction within that space,” Mancini stated in the debut episode of RadOnc on the Run. “As we know, about 50% to 60% of patients receive radiation therapy during their cancer journey. Continuing to enhance the coverage within radiation oncology and ensure that its importance is reviewed on a routine basis is very important and something we aim to do here.”